GSK 3206640A

Drug Profile

GSK 3206640A

Alternative Names: GSK Biologicals' influenza vaccine GSK3206640A; GSK-3206640A

Latest Information Update: 11 Feb 2015

Price : $50

At a glance

  • Originator GlaxoSmithKline Biologicals
  • Class Influenza A virus H7N9 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Influenza A virus H7N9 subtype

Most Recent Events

  • 03 Feb 2015 GlaxoSmithKline completes a phase I trial in Influenza-A virus H7N9 subtype (prevention, in adults, in volunteers) in USA and Canada (NCT01999842)
  • 30 Nov 2013 Phase-I clinical trials in Influenza-A virus H7N9 subtype (prevention in adult volunteers) in Canada (IM) (NCT01999842)
  • 30 Nov 2013 Phase-I clinical trials in Influenza-A virus H7N9 subtype (prevention in adult volunteers) in USA (IM) (NCT01999842)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top